Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Gossamer Bio, Inc. (GOSS) since 2019 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Gossamer Bio, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1728117.
Total stock buying since 2019: $4,432,720.
Total stock sales since 2019: $11,119,665.
Total stock option exercises since 2019: $449,755.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 26,050 | $50,016 | 0 | $0 | 0 | $0 |
| 2024 | 497,000 | $324,506 | 45,976 | $53,576 | 0 | $0 |
| 2023 | 1,034,072 | $1,152,277 | 22,970 | $25,568 | 0 | $0 |
| 2022 | 166,433 | $1,199,981 | 69,886 | $600,193 | 0 | $0 |
| 2021 | 0 | $0 | 12,622 | $139,408 | 0 | $0 |
| 2020 | 104,020 | $1,079,818 | 0 | $0 | 0 | $0 |
| 2019 | 37,871 | $626,122 | 491,994 | $10,300,920 | 41,994 | $449,755 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 26,050 | $50,016 | 0 | $0 | 0 | $0 |
| 2024-06 | 497,000 | $324,506 | 1,908 | $1,261 | 0 | $0 |
| 2024-03 | 0 | $0 | 44,068 | $52,315 | 0 | $0 |
| 2023-11 | 32,000 | $25,216 | 0 | $0 | 0 | $0 |
| 2023-06 | 0 | $0 | 1,814 | $2,340 | 0 | $0 |
| 2023-04 | 55,000 | $56,100 | 0 | $0 | 0 | $0 |
| 2023-03 | 947,072 | $1,070,961 | 21,156 | $23,228 | 0 | $0 |
| 2022-07 | 166,433 | $1,199,981 | 8,808 | $72,648 | 0 | $0 |
| 2022-06 | 0 | $0 | 1,778 | $12,232 | 0 | $0 |
| 2022-05 | 0 | $0 | 1,262 | $9,086 | 0 | $0 |
| 2022-03 | 0 | $0 | 58,038 | $506,227 | 0 | $0 |
| 2021-10 | 0 | $0 | 7,131 | $87,354 | 0 | $0 |
| 2021-03 | 0 | $0 | 5,491 | $52,054 | 0 | $0 |
| 2020-10 | 102,020 | $1,053,896 | 0 | $0 | 0 | $0 |
| 2020-06 | 2,000 | $25,922 | 0 | $0 | 0 | $0 |
| 2019-12 | 0 | $0 | 41,994 | $631,535 | 41,994 | $449,755 |
| 2019-09 | 22,121 | $371,422 | 400,000 | $8,675,343 | 0 | $0 |
| 2019-08 | 0 | $0 | 50,000 | $994,042 | 0 | $0 |
| 2019-05 | 1,000 | $18,700 | 0 | $0 | 0 | $0 |
| 2019-02 | 14,750 | $236,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-19 | Milligan Sandra (Director) | Buy | 26,050 | 1.92 | 50,016 |
| 2024-06-24 | Aranda Richard (Chief Medical Officer) | Sale | 1,908 | .66 | 1,261 |
| 2024-06-21 | Hasnain Faheem (President & CEO) | Buy | 372,000 | .67 | 250,356 |
| 2024-06-18 | Giraudo Bryan (COO/CFO) | Buy | 100,000 | .59 | 59,100 |
| 2024-06-17 | Smith Robert Paul Jr (Chief Commercial Officer) | Buy | 25,000 | .60 | 15,050 |
| 2024-03-27 | Giraudo Bryan (COO/CFO) | Sale | 6,430 | 1.16 | 7,433 |
| 2024-03-27 | Christian Waage (EVP, Tech Ops and Admin) | Sale | 6,430 | 1.16 | 7,433 |
| 2024-03-27 | Hasnain Faheem (President & CEO) | Sale | 23,172 | 1.16 | 26,763 |
| 2024-03-18 | Aranda Richard (Chief Medical Officer) | Sale | 4,018 | 1.33 | 5,343 |
| 2024-03-18 | Peterson Caryn (EVP, Regulatory Affairs) | Sale | 4,018 | 1.33 | 5,343 |
| 2023-11-15 | Milligan Sandra (Director) | Buy | 32,000 | .79 | 25,216 |
| 2023-06-22 | Aranda Richard (Chief Medical Officer) | Sale | 1,814 | 1.29 | 2,340 |
| 2023-04-04 | Giraudo Bryan (COO/CFO) | Buy | 55,000 | 1.02 | 56,100 |
| 2023-03-22 | Hasnain Faheem (President & CEO) | Buy | 440,500 | 1.14 | 503,491 |
| 2023-03-21 | Hasnain Faheem (President & CEO) | Buy | 269,389 | 1.20 | 322,458 |
| 2023-03-20 | Giraudo Bryan (COO/CFO) | Buy | 50,000 | .97 | 48,450 |
| 2023-03-20 | Christian Waage (EVP, Tech Ops and Admin) | Buy | 18,500 | 1.20 | 22,144 |
| 2023-03-20 | Hasnain Faheem (President & CEO) | Buy | 168,683 | 1.03 | 174,418 |
| 2023-03-16 | Aranda Richard (Chief Medical Officer) | Sale | 7,563 | 1.10 | 8,304 |
| 2023-03-16 | Carter Laura (Chief Scientific Officer) | Sale | 6,029 | 1.10 | 6,619 |
| 2023-03-16 | Peterson Caryn (EVP, Regulatory Affairs) | Sale | 7,564 | 1.10 | 8,305 |
| 2022-07-15 | Carter Laura (Chief Scientific Officer) | Buy | 6,934 | 7.21 | 49,994 |
| 2022-07-15 | Giraudo Bryan (COO/CFO) | Buy | 13,869 | 7.21 | 99,995 |
| 2022-07-15 | Christian Waage (EVP, Tech Ops and Admin) | Buy | 6,934 | 7.21 | 49,994 |
| 2022-07-15 | Hasnain Faheem (President & CEO) | Buy | 138,696 | 7.21 | 999,998 |
| 2022-07-01 | Carter Laura (Chief Scientific Officer) | Sale | 8,808 | 8.25 | 72,648 |
| 2022-06-22 | Aranda Richard (Chief Medical Officer) | Sale | 1,778 | 6.88 | 12,232 |
| 2022-05-04 | Carter Laura (Chief Scientific Officer) | Sale | 1,262 | 7.20 | 9,086 |
| 2022-03-23 | Giraudo Bryan (COO/CFO) | Sale | 10,722 | 8.91 | 95,586 |
| 2022-03-23 | Christian Waage (EVP, Tech Ops and Admin) | Sale | 10,722 | 8.91 | 95,586 |
| 2022-03-23 | Hasnain Faheem (President & CEO) | Sale | 19,035 | 8.91 | 169,697 |
| 2022-03-16 | Aranda Richard (Chief Medical Officer) | Sale | 6,278 | 8.28 | 51,975 |
| 2022-03-16 | Carter Laura (Chief Scientific Officer) | Sale | 5,002 | 8.28 | 41,406 |
| 2022-03-16 | Peterson Caryn (EVP, Regulatory Affairs) | Sale | 6,279 | 8.28 | 51,977 |
| 2021-10-25 | Aranda Richard (Chief Medical Officer) | Sale | 2,377 | 12.25 | 29,118 |
| 2021-10-25 | Carter Laura (Chief Scientific Officer) | Sale | 2,377 | 12.25 | 29,118 |
| 2021-10-25 | Peterson Caryn (EVP, Regulatory Affairs) | Sale | 2,377 | 12.25 | 29,118 |
| 2021-03-23 | Salter-cid Luisa (Chief Scientific Officer) | Sale | 5,491 | 9.48 | 52,054 |
| 2020-10-14 | Giraudo Bryan (Chief Financial Officer) | Buy | 3,000 | 10.01 | 30,036 |
| 2020-10-14 | Christian Waage (EVP & General Counsel) | Buy | 2,500 | 9.53 | 23,817 |
| 2020-10-14 | Hasnain Faheem (Director) | Buy | 96,520 | 10.36 | 1,000,043 |
| 2020-06-23 | Giraudo Bryan (Chief Financial Officer) | Buy | 2,000 | 12.96 | 25,922 |
| 2019-12-30 | Dupont Jakob (Chief Medical Officer) | Sale | 40,000 | 15.00 | 600,000 |
| 2019-12-30 | Dupont Jakob (Chief Medical Officer) | Option Ex | 40,000 | 10.71 | 428,400 |
| 2019-12-27 | Dupont Jakob (Chief Medical Officer) | Sale | 1,994 | 15.81 | 31,535 |
| 2019-12-27 | Dupont Jakob (Chief Medical Officer) | Option Ex | 1,994 | 10.71 | 21,355 |
| 2019-09-27 | Gujrathi Sheila (President & CEO) | Buy | 10,000 | 16.80 | 167,979 |
| 2019-09-27 | Christian Waage (EVP & General Counsel) | Buy | 1,000 | 16.65 | 16,654 |
| 2019-09-27 | Hasnain Faheem (Director) | Buy | 10,000 | 16.80 | 167,979 |
| 2019-09-26 | Giraudo Bryan (Chief Financial Officer) | Buy | 1,121 | 16.78 | 18,810 |
| 2019-09-20 | Omega Fund V Gp Manager, Ltd. (10% Owner) | Sale | 183,607 | 21.96 | 4,032,560 |
| 2019-09-18 | Stampacchia Otello (Other) | Sale | 45,600 | 21.88 | 997,636 |
| 2019-09-17 | Stampacchia Otello (Other) | Sale | 23,400 | 21.61 | 505,790 |
| 2019-09-16 | Stampacchia Otello (Other) | Sale | 13,213 | 21.52 | 284,330 |
| 2019-09-11 | Stampacchia Otello (Director) | Sale | 80,403 | 21.31 | 1,713,629 |
| 2019-09-10 | Stampacchia Otello (Director) | Sale | 32,373 | 21.00 | 679,865 |
| 2019-09-06 | Stampacchia Otello (Director) | Sale | 8,700 | 21.51 | 187,102 |
| 2019-09-05 | Stampacchia Otello (Director) | Sale | 12,704 | 21.60 | 274,431 |
| 2019-08-29 | Salter-cid Luisa (Chief Scientific Officer) | Sale | 26,252 | 20.09 | 527,323 |
| 2019-08-28 | Salter-cid Luisa (Chief Scientific Officer) | Sale | 23,748 | 19.65 | 466,719 |
| 2019-05-30 | Giraudo Bryan (Chief Financial Officer) | Buy | 1,000 | 18.70 | 18,700 |
| 2019-02-12 | Giraudo Bryan (Chief Financial Officer) | Buy | 6,000 | 16.00 | 96,000 |
| 2019-02-12 | Christian Waage (EVP & General Counsel) | Buy | 1,550 | 16.00 | 24,800 |
| 2019-02-12 | Cox Russell J. (Director) | Buy | 7,200 | 16.00 | 115,200 |
Insider trading activities including stock purchases, stock sales, and option exercises of GOSS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Gossamer Bio, Inc. (symbol GOSS, CIK number 1728117) see the Securities and Exchange Commission (SEC) website.